Annual General Meeting of BioGaia

The Annual General Meeting of BioGaia AB (publ) on 5 May 2023 voted, among other things, to approve the following resolutions:

  • adoption of the income statement and balance sheet and the consolidated income statement and consolidated balance sheet
  • discharge from liability for the Board members and the CEO
  • a dividend of SEK 1.45 per share plus an extra dividend of SEK 1.45 per share resulting in a total dividend of SEK 2.90 per share and a grant of SEK 4.4 million to “The Foundation to Prevent Antibiotic Resistance” that was founded by BioGaia in 2017. The purpose of the foundation is to reduce antibiotic resistance through support to research, education and information activities that promote of the use of products and methods that prevent and therefore reduce the use of antibiotics and the risk of antibiotic resistance
  • to amend the Articles of Association to enable the collection of proxies and postal voting for future general meetings
  • the number of Board members shall be eight without deputies and re-election of Anthon Jahreskog, Bénédicte Flambard, David Dangoor, Peter Rothschild and Vanessa Rothschild and new election of Barbro Fridén, Outi Armstrong and Vesa Koskinen as Board members
  • re-election of Peter Rothschild as board chairman and David Dangoor as deputy Board chairman
  • the auditor shall be a registered accounting firm and re-election of the registered accounting firm Deloitte AB
  • board member remuneration in an amount of SEK 710,000 to the Board chairman, SEK 490,000 to the deputy Board chairman, SEK 275,000 to each of the other Board members elected by the general meeting, SEK 110,000 to the chairman of the audit committee and SEK 55,000 each to the other members of the audit committee and SEK 45,000 to the chairman of the remuneration committee and SEK 20,000 to each to the other members of the remuneration committee
  • an additional, monthly remuneration of not more than SEK 50,000 to the chairman of the Board for duties in addition to the assignment as chairman of the Board. Any such additional remuneration shall be paid according to separate agreement and the Board’s detailed decision
  • auditors’ fee shall be paid according to approved account
  • on a nominating committee in accordance with the nominating committee’s proposal, and
  • approval of the Board of Director’s remuneration report.


Follow us:
Subscribe to BioGaia press releases here
LinkedIn here

Isabelle Ducellier, CEO
Email: [email protected]
Phone: +46 701 91 73 62

Alexander Kotsinas, CFO
Email: [email protected]
Phone: +46 735 00 11 11

About BioGaia
BioGaia is an innovative Swedish healthcare company that develops, markets, and sells probiotic products with documented health benefits. The products are sold through local distribution partners or via own distribution in over 100 markets. The class B share of the Parent Company BioGaia AB is quoted on the Mid Cap segment of Nasdaq Stockholm.